Tomorrow, another all-round listed pharmaceutical company will be added in Guangzhou!

On November 14, according to the Shenzhen Stock Exchange, the RMB common stock of yipinhong Pharmaceutical Co., Ltd will be listed on the gem of the exchange on November 16, 2017 The securities are abbreviated as "Poinsettia" and the securities code is "300723" The total number of RMB common shares of the company is 160000000, of which 40000000 shares are listed and traded since the date of listing According to the official website of poinsettia, with a registered capital of 120 million yuan, poinsettia is a modern pharmaceutical enterprise focusing on pharmaceutical R & D, production and sales The company has three wholly-owned subsidiaries and one holding subsidiary Guangzhou yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, is a modern pharmaceutical production enterprise with chemical drugs and traditional Chinese medicine products as the core From its products on the market, we can also see the positioning of both corporate medicine and traditional Chinese medicine According to the latest information in the domestic drug database of pharma intelligence, there are 134 listed drug messages (calculated according to the approval number, the same below), including 98 chemical drugs and 36 traditional Chinese medicines Among them, 45 have been included in class B medical insurance and 34 have been included in class a medical insurance At present, only poinsettia is in production in China, such as compound Elsholtzia water, Huixinkang tablet, Fuganlin oral liquid, yiqijianpi oral liquid, qinxiangqingjie oral liquid and Shenbai lotion Chemicals such as dextrisoclonidine hydrochloride, clindamycin palmitate hydrochloride dispersible tablets, gentian soda tablets, acetylkitasamycin dry suspension, clindamycin palmitate hydrochloride dispersible tablets are only produced by this enterprise In addition, poinsettia has new considerations in new drug research and development According to the database of drug registration and acceptance, there are 16 products (calculated by acceptance number, the same below) that are being applied for approval, including 5 traditional Chinese medicines and 11 chemical drugs Among them, only valsartan amlodipine tablets (I), a chemical product of category 6, have been approved.